Recent News

June 25, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Added to the Russell 3000® Index

BOSTON , June 25, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
June 6, 2018 at 4:05 PM EDT

Summary Toggle Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy

Results Show Statistically Significant Improvement in Sweat Chloride, Body Mass Index, Weight and Blood Glucose Treatment Led to a Statistically Significant Improvement in Blood Glucose Levels and the Reversal of Hyperglycemia in a Diabetic CF Subpopulation Improvement in FEV1 Observed Across All
June 1, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference

BOSTON , June 1, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
May 31, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

BOSTON , May 31, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
May 8, 2018 at 7:00 AM EDT

Summary Toggle Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis

Program to Pursue Broad Label for PTI-428 as an Add-On Therapy to CFTR Modulator Based Treatment BRIGHTON, Mass. , May 8, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking
April 17, 2018 at 7:10 AM EDT

Summary Toggle Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy

Phase 2 Study of PTI-428 + Symdeko Planned to Initiate in 3Q'18; Study Intended to Expand Population of CF subjects in Phase 3 to Include Both Orkambi and Symdeko Standard of Care CAMBRIDGE, Mass. , April 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
April 4, 2018 at 6:00 AM EDT

Summary Toggle Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis

CAMBRIDGE, Mass. , April 4, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 20, 2018 at 7:59 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

CAMBRIDGE, Mass. , March 20, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 19, 2018 at 4:01 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , March 19, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein
March 14, 2018 at 5:29 PM EDT

Summary Toggle Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update

14-day Study of PTI-801, Company’s Third Generation Corrector, in CF Patients on Background Orkambi ® Enrolling Ahead of Schedule; Results from All Three Cohorts Expected Q2'18 Company Announces Additional Study of PTI-428 in CF Subjects on Symdeko™ to Support Path to NDA, with Initial Data